No profile data available.
Apnimed, Inc. (APMD) is a listed company, based in Cambridge, United States, with about 81 full-time employees.
It reported revenue of $38.47 million for fiscal year 2025, up 380.1% from fiscal year 2024, and net income of -$932,000. In Q2 2026 (the quarter ended June 30, 2026) revenue was $12.08 million, down 29.4% from a year before. Its market capitalization was $771.00 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. It offers AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction.
Apnimed reported $38.47 million in revenue for fiscal year 2025, up 380.1% from $8.01 million in fiscal year 2024. In Q2 2026 revenue was $12.08 million.
$771.00 million as of October 9, 2026.